Biosimilars: Company Strategies to Capture Value from the Biologics Market
Patents for several biologic blockbusters will expire in the next few years. The arrival of biosimilars, the biologic equivalent of chemical generics, will have an impact on the current biopharmaceuticals market. Five core capabilities have been identified as paramount for those companies aiming to...
Saved in:
Main Authors: | Juan Leonardo Martínez-Hurtado (Author), Bruno Calo-Fernández (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2012-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Emerging Insights into European Markets of Biologics, Including Biosimilars
by: Steven Simoens, et al.
Published: (2022) -
Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis
by: Yannick Vandenplas, et al.
Published: (2021) -
Development of Marketing Strategy on the Example of it Company
by: Iryna Boryshkevych, et al.
Published: (2023) -
Influence of European Market Dynamics on Biosimilars Market Share
by: Diogo Pires, et al.
Published: (2016) -
Key drivers for market penetration of biosimilars in Europe
by: Cécile Rémuzat, et al.
Published: (2017)